What Made Mizuho Securities Upgrade Satsuma Pharmaceuticals Stock?
In a report released today, Vamil Divan from Mizuho Securities upgraded Satsuma Pharmaceuticals (STSA  Research Report) to Buy, with a price target of $15.00. The companys shares closed last Monday at $5.54, close to its 52-week low of $3.50. According to TipRanks.com, Divan is a 3-star analyst with an average return of 1.4% and a 53.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Revance Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Satsuma Pharmaceuticals with a $12.17 average price target, which is an 117.7% upside from current levels. In a report issued on June 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target. See todays analyst top recommended stocks >>  Based on Satsuma Pharmaceuticals latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.48 million. In comparison, last year the company had a GAAP net loss of $11.81 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.